Home > Boards > US Listed > Medical - Healthcare > Acasti Pharma, Inc (ACST)

RE:RE:What is Chen Buying? What is Chen Selling?

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
JB3729 Member Profile
 
Followed By 83
Posts 3,868
Boards Moderated 0
Alias Born 02/15/10
160x600 placeholder
Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference GlobeNewswire Inc. - 1/3/2022 8:30:00 AM
Acasti Pharma jumps 21% on new Outperform rating at Oppenheimer with PT of $6 Seeking Alpha - 12/22/2021 7:16:57 AM
Acasti says candidate for subarachnoid hemorrhage met main goals in pivotal PK study Seeking Alpha - 12/2/2021 7:40:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/2/2021 7:17:49 AM
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104 GlobeNewswire Inc. - 12/2/2021 7:00:00 AM
Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd GlobeNewswire Inc. - 11/24/2021 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/16/2021 4:21:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/16/2021 4:21:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/16/2021 4:20:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/16/2021 4:20:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/16/2021 4:19:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/16/2021 4:17:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/15/2021 6:07:42 AM
Acasti Pharma Announces Annual Stock Option Grants GlobeNewswire Inc. - 11/12/2021 5:34:47 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/10/2021 7:24:49 AM
Acasti Pharma EPS beats by $0.60 Seeking Alpha - 11/10/2021 7:20:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/10/2021 7:09:48 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/10/2021 7:02:37 AM
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022 GlobeNewswire Inc. - 11/10/2021 7:00:00 AM
Acasti Pharma Q2 Earnings Preview Seeking Alpha - 11/9/2021 1:07:09 PM
Notable earnings before Wednesday's open Seeking Alpha - 11/9/2021 11:17:08 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/5/2021 4:08:33 PM
Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call GlobeNewswire Inc. - 11/4/2021 8:30:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 11/3/2021 4:34:21 PM
Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan GlobeNewswire Inc. - 10/6/2021 8:30:00 AM
JB3729   Wednesday, 01/02/19 11:20:12 AM
Re: None
Post # of 1116 
RE:RE:What is Chen Buying? What is Chen Selling?

More from Chen -

11/16/18 -
Biotechs are in deep corrections. My sense is that this is a good time to buy quality stocks at deep discount. I recently asked a good friend of mine who is a very experienced biotech guy. If I put a gun to your head, which of the biotechs you would buy now? He told me it would be Acasti Pharma Inc. (ACST) and Viking Therapeutics, Inc. (VKTX). ACST is truly beyond reasoning here, he said. They are full funded to phase 3 results and raised at one dollar without warrants. Trial results will start to come out in Q3 of 2019. AMRN already recovered, they will likely get the FDA approval for expansion of label in 2019. Next time this year, with positive results that we are expecting, he strongly believes ACST will be the best in class and should be trading at least 5+.

11/28/18 -
I had a good meeting with Acasti Pharma Inc. (ACST) management yesterday. They came to New York to marketing their company finally. They are fully funded for the two phase 3 next year. The first phase 3 will finish enrollment in December and trial readout can come out as early as Q3 of 2019. The second trial is about 3 month behind and will be finished by the end of 2019. They are working on partnerships around the world and could bring extra money and collaborations. They are also working on other indications. They want to complete pre-clinical trials to support Capre lower the blood sugar. Lower A1C was one of the secondary end points of the current two phase 3 trials. They want to be able to include it in the label if the trial goes as they hoped. Oppenheimer plans to launch research coverage in January. I think once the tax loss selling is finished, excitement could build ahead of next year's data. On valuation, ACST is very very cheap. Even based on AMRN pre-REDUCE-IT half a billion market cap. It should worth that much, or $5/share. If the data is spectacular as we hoped, Capre can be the next Lipitor that took the majority of the market share WITHOUT an outcome study like REDUCE-IT. In that case, ACST can worth $20-50/share or more. After all, the patients want and deserve only the best.

Read more at http://www.stockhouse.com/companies/bullboard?symbol=v.acst&postid=29176815#tv7UIMGaYpBpGMr0.99

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences